Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Lowers Forecast As Q3 Revenues Decline Amid Growing Generic Competition
But Opioid Crisis Settlement On Track
Nov 03 2022
•
By
Ayisha Sharma
Teva's Profits Have Dipped Despite Lower R&D Spend • Source: Shutterstock
More from Business
More from Scrip